中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
10期
197-198
,共2页
阿托伐他汀钙%冠心病%心功能不全
阿託伐他汀鈣%冠心病%心功能不全
아탁벌타정개%관심병%심공능불전
Atorvastatin%Coronary heart disease%Heart failure
目的分析探讨阿托伐他汀钙药物是否降低冠心病心功能不全患者的肾功能损害,对其产生保护作用。方法以45例冠心病心功能不全并伴有肾功能异常的患者作为研究对象,将其随机分为治疗组和对照组,对照组22例患者采用常规药物进行治疗,治疗组23例患者在常规治疗基础上联合阿托伐他汀钙共同进行治疗,对45例患者进行治疗后随访,对比分析两组患者治疗前后的肾功能指标情况。结果两组各有21例患者参加治疗后第12个月肾功能情况的对比分析。治疗组21例患者的肾功能指标(肾小球滤过率和胱抑素)优于对照组的21例患者,P<0.05,差异具有统计学意义,而两组患者的2微球蛋白指标,P>0.05,差异不具有统计学意义。结论应用阿托伐他汀钙药物对冠心病心功能不全并伴有肾功能异常的患者进行辅助治疗,可明显降低其肾功能的损害程度,产生保护作用。
目的分析探討阿託伐他汀鈣藥物是否降低冠心病心功能不全患者的腎功能損害,對其產生保護作用。方法以45例冠心病心功能不全併伴有腎功能異常的患者作為研究對象,將其隨機分為治療組和對照組,對照組22例患者採用常規藥物進行治療,治療組23例患者在常規治療基礎上聯閤阿託伐他汀鈣共同進行治療,對45例患者進行治療後隨訪,對比分析兩組患者治療前後的腎功能指標情況。結果兩組各有21例患者參加治療後第12箇月腎功能情況的對比分析。治療組21例患者的腎功能指標(腎小毬濾過率和胱抑素)優于對照組的21例患者,P<0.05,差異具有統計學意義,而兩組患者的2微毬蛋白指標,P>0.05,差異不具有統計學意義。結論應用阿託伐他汀鈣藥物對冠心病心功能不全併伴有腎功能異常的患者進行輔助治療,可明顯降低其腎功能的損害程度,產生保護作用。
목적분석탐토아탁벌타정개약물시부강저관심병심공능불전환자적신공능손해,대기산생보호작용。방법이45례관심병심공능불전병반유신공능이상적환자작위연구대상,장기수궤분위치료조화대조조,대조조22례환자채용상규약물진행치료,치료조23례환자재상규치료기출상연합아탁벌타정개공동진행치료,대45례환자진행치료후수방,대비분석량조환자치료전후적신공능지표정황。결과량조각유21례환자삼가치료후제12개월신공능정황적대비분석。치료조21례환자적신공능지표(신소구려과솔화광억소)우우대조조적21례환자,P<0.05,차이구유통계학의의,이량조환자적2미구단백지표,P>0.05,차이불구유통계학의의。결론응용아탁벌타정개약물대관심병심공능불전병반유신공능이상적환자진행보조치료,가명현강저기신공능적손해정도,산생보호작용。
Objective To explore whether atorvastatin calcium drugs decreased heart function of coronary heart disease in the patients with renal insufifciency have a protective effect on the damage.Methods In 45 patients with coronary heart disease cardiac dysfunction and associated with abnormal renal function as the object of study, which were randomly separated into treatment group and control group, 22 cases in the control group were treated with routine drug treatment, treatment group based on conventional therapy plus atorvastatin calcium common treatment, 45 patients were followed up after the treatment, the contrast analysis of renal function indexes of two groups of patients before and after treatment. ResultsTwo groups compared with patients in twelfth months after treatment renal function condition. The treatment group of 21patients with renal function index 21 cases were signiifcantly better than the control group of patients, but no significant difference between all patients2 microglobulin index (P>0.05).Conclusion Atorvastatin calcium drugs on coronary heart disease cardiac dysfunction and associated with abnormal renal function in patients with adjuvant therapy, can significantly reduce damage of kidney function.